IKZF1 and precursor B-cell acute lymphoblastic leukemia: Multiple studies support that IKZF1 mutation/deletion is an independent indicator of B-ALL unfavorable clinical outcome including chemotherapy resistance and higher risk for relapse [27, 46, 59–61].